Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

GT Biopharma (GTBP) Total Current Liabilities (2016 - 2021)

GT Biopharma (GTBP) has disclosed Total Current Liabilities for 12 consecutive years, with $3.9 million as the latest value for Q3 2021.

  • On a quarterly basis, Total Current Liabilities fell 87.22% to $3.9 million in Q3 2021 year-over-year; TTM through Sep 2021 was $3.9 million, a 87.22% decrease, with the full-year FY2020 number at $35.1 million, up 78.09% from a year prior.
  • Total Current Liabilities was $3.9 million for Q3 2021 at GT Biopharma, up from $3.3 million in the prior quarter.
  • In the past five years, Total Current Liabilities ranged from a high of $35.1 million in Q4 2020 to a low of $2.7 million in Q4 2017.
  • A 5-year average of $14.9 million and a median of $16.1 million in 2019 define the central range for Total Current Liabilities.
  • Peak YoY movement for Total Current Liabilities: skyrocketed 371.91% in 2018, then crashed 88.53% in 2021.
  • GT Biopharma's Total Current Liabilities stood at $2.7 million in 2017, then skyrocketed by 393.58% to $13.2 million in 2018, then surged by 49.03% to $19.7 million in 2019, then soared by 78.09% to $35.1 million in 2020, then crashed by 88.82% to $3.9 million in 2021.
  • Per Business Quant, the three most recent readings for GTBP's Total Current Liabilities are $3.9 million (Q3 2021), $3.3 million (Q2 2021), and $3.6 million (Q1 2021).